RI
RTW Investments Portfolio holdings
AUM
$7.02B
This Quarter Return
+5.22%
1 Year Return
+28.16%
3 Year Return
+245.48%
5 Year Return
+425.65%
10 Year Return
+5,642.23%
AUM
$6.61B
AUM Growth
+$6.61B
(-4.3%)
Cap. Flow
-$127M
Cap. Flow
% of AUM
-1.92%
Top 10 Holdings %
Top 10 Hldgs %
48.57%
Holding
77
New
9
Increased
21
Reduced
16
Closed
5
Top Buys
| 1 |
VRNA
Verona Pharma
VRNA
|
$84.6M |
| 2 |
Globus Medical
GMED
|
$80.4M |
| 3 |
Stryker
SYK
|
$69.6M |
| 4 |
Zai Lab
ZLAB
|
$65.7M |
| 5 |
Xencor
XNCR
|
$42M |
Top Sells
| 1 |
Geron
GERN
|
$200M |
| 2 |
Masimo
MASI
|
$129M |
| 3 |
Acadia Pharmaceuticals
ACAD
|
$91.8M |
| 4 |
Bruker
BRKR
|
$58.6M |
| 5 |
Glaukos
GKOS
|
$50.3M |
Sector Composition
| 1 | Healthcare | 99.89% |
| 2 | Financials | 0.11% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Madrigal Pharmaceuticals
MDGL
$9.76B
| $615M | 9.3% | 1,993,687 | – | – |
|
2
argenx
ARGX
$43.6B
| $414M | 6.26% | 673,497 +19,067 | +3% | +$11.7M |
|
3
Natera
NTRA
$23.1B
| $411M | 6.21% | 2,593,323 | – | – |
|
4
Axsome Therapeutics
AXSM
$6.05B
| $343M | 5.18% | 4,051,365 -138,192 | -3% | -$11.7M |
|
5
PTC Therapeutics
PTCT
$3.92B
| $334M | 5.05% | 7,393,127 | – | – |
|
6
Avidity Biosciences
RNA
$5.99B
| $231M | 3.49% | 7,932,870 -200,000 | -2% | -$5.82M |
|
7
Rocket Pharmaceuticals
RCKT
$354M
| $222M | 3.36% | 17,687,772 | – | – |
|
8
Alkermes
ALKS
$4.78B
| $217M | 3.29% | 7,557,835 +903,802 | +14% | +$26M |
|
|
9
Stryker
SYK
$150B
| $213M | 3.21% | 590,221 +193,300 | +49% | +$69.6M |
|
10
Protagonist Therapeutics
PTGX
$3.67B
| $212M | 3.21% | 5,498,545 +72,433 | +1% | +$2.8M |
|
11
Insmed
INSM
$28.8B
| $208M | 3.15% | 3,014,558 -257,450 | -8% | -$17.8M |
|
12
Penumbra
PEN
$10.6B
| $205M | 3.1% | 862,450 +66,700 | +8% | +$15.8M |
|
13
Akero Therapeutics
AKRO
$3.74B
| $191M | 2.89% | 6,859,823 +940,388 | +16% | +$26.2M |
|
14
Tarsus Pharmaceuticals
TARS
$2.47B
| $179M | 2.71% | 3,236,549 -175,937 | -5% | -$9.74M |
|
15
Merus
MRUS
$4.98B
| $175M | 2.65% | 4,169,393 | – | – |
|
|
16
Acadia Pharmaceuticals
ACAD
$4.38B
| $160M | 2.42% | 8,705,501 -5,002,005 | -36% | -$91.8M |
|
|
17
Bruker
BRKR
$5.16B
| $145M | 2.2% | 2,481,119 -1,000,000 | -29% | -$58.6M |
|
18
Immunocore
IMCR
$1.62B
| $144M | 2.17% | 4,869,798 | – | – |
|
19
RadNet
RDNT
$5.52B
| $138M | 2.09% | 1,978,582 +169,978 | +9% | +$11.9M |
|
20
Cytokinetics
CYTK
$4.23B
| $128M | 1.94% | 2,721,158 | – | – |
|
21
Dyne Therapeutics
DYN
$1.92B
| $123M | 1.86% | 5,218,641 -1,600,000 | -23% | -$37.7M |
|
22
Apogee Therapeutics
APGE
$2.17B
| $123M | 1.86% | 2,712,097 +1 | +0% | +$45 |
|
23
Establishment Labs
ESTA
$1.2B
| $118M | 1.79% | 2,569,687 -76,016 | -3% | -$3.5M |
|
|
24
Masimo
MASI
$7.59B
| $113M | 1.71% | 683,294 -779,106 | -53% | -$129M |
|
|
VRNA
25
Verona Pharma
VRNA
$9.16B
| $84.6M | 1.28% | +1,821,019 | New | +$84.6M |
|